国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

Biosensors International 柏盛國際
 介入性心臟治療和急救護理程序的創(chuàng)新醫(yī)療設(shè)備生產(chǎn)商
Biomatrix藥物涂層心血管支架

 

Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients’ lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix? family of drug-eluting stents and the recent launch of our Axxess? self-expanding bifurcation drug-eluting stent, we are rapidly emerging as a leader in the global coronary stent market. The development of the BioFreedom? drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9? (BA9?), an anti-restenotic drug developed and patented by Biosensors specifically for use with stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer‐free stent abluminally coated with BA9, received CE Mark Approval in January 2013.